Home Metabolism phosphatase inhibitor BBP- 398 (IACS-13909) For research use only.

BBP- 398 (IACS-13909)

BBP- 398 (IACS-13909) is a specific and potent allosteric inhibitor of SHP2 (Src homology 2 domain-containing phosphatase) that suppresses signaling through the MAPK pathway.

BBP- 398 (IACS-13909) Chemical Structure

BBP- 398 (IACS-13909) Chemical Structure

CAS: 2160546-07-4

Selleck's BBP- 398 (IACS-13909) has been cited by 1 publication

Purity & Quality Control

Batch: Purity: 99.99%
99.99

BBP- 398 (IACS-13909) Related Products

Choose Selective phosphatase Inhibitors

Biological Activity

Description BBP- 398 (IACS-13909) is a specific and potent allosteric inhibitor of SHP2 (Src homology 2 domain-containing phosphatase) that suppresses signaling through the MAPK pathway.
Targets
SHP2 [1]
In vitro
In vitro

IACS-13909 is a specific and potent allosteric inhibitor of SHP2 that suppresses signaling through the MAPK pathway. IACS-13909 potently impedes proliferation of tumors harboring a broad spectrum of activated RTKs as the oncogenic driver. IACS-13909 potently suppresses tumor cell proliferation in vitro.[1]
Cell Research Cell lines KYSE-520 cells
Concentrations 0-10000 nM
Incubation Time 2 h
Method

KYSE-520 cells are seeded (10,000 cells/40 µL/well) in 384-well tissue culture plates. The next day, cells are treated with DMSO or serially diluted IACS-13909 for 2 hours at 37℃, 5% CO2. Phospho-ERK levels are measured using AlphaScreen SureFire ERK1/2 (phospho‐Thr202/Tyr204) assay kit following manufacturer's recommendations. AlphaScreen signal is measured on an Envision plate reader using default AlphaScreen settings. Dose-response curves are analyzed using IC50 regression curve fitting.
In Vivo
In vivo

In EGFR-mutant osimertinib-resistant NSCLC models with EGFR-dependent and EGFR-independent resistance mechanisms, IACS-13909, administered as a single agent or in combination with osimertinib, causes tumor regression in vivo.[1]
Animal Research Animal Models female CD1 mice; Sprague Dawley (SD) male rats; male adult beagle dogs
Dosages 0.3 mg/kg, 10 mg/kg; 1 mg/kg, 3 mg/kg; 0.3 mg/kg, 1 mg/kg
Administration IV, Oral gavage
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05621525 Recruiting
Advanced Solid Tumor|Advanced or Metastatic Non-small Cell Lung Cancer
LianBio LLC
 October 18 2022 Phase 1
NCT05375084 Recruiting
Non Small Cell Lung Cancer|Solid Tumor
Navire Pharma Inc. a BridgeBio company|Bristol-Myers Squibb
 October 20 2022 Phase 1
NCT05480865 Recruiting
Solid Tumor Adult|Metastatic Solid Tumor|Metastatic NSCLC|Non Small Cell Lung Cancer
Navire Pharma Inc. a BridgeBio company|Amgen
 July 6 2022 Phase 1
NCT04528836 Recruiting
Tumor Solid
Navire Pharma Inc. a BridgeBio company
 November 12 2020 Phase 1

Chemical Information & Solubility

Molecular Weight 377.27 Formula

C17H18Cl2N6
CAS No. 2160546-07-4 SDF --
Smiles CC1(N)CCN(CC1)C2=CN=C3C(=N2)[NH]N=C3C4=CC=CC(=C4Cl)Cl
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 75 mg/mL ( (198.79 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy BBP- 398 (IACS-13909) | BBP- 398 (IACS-13909) supplier | purchase BBP- 398 (IACS-13909) | BBP- 398 (IACS-13909) cost | BBP- 398 (IACS-13909) manufacturer | order BBP- 398 (IACS-13909) | BBP- 398 (IACS-13909) distributor